Island Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Island Pharmaceuticals's earnings have been declining at an average annual rate of -24.3%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 89.1% per year.
Key information
-24.3%
Earnings growth rate
29.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 89.1% |
| Return on equity | -372.4% |
| Net Margin | -247.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Island Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -2 | 2 | 1 |
| 30 Sep 23 | 0 | -3 | 2 | 1 |
| 30 Jun 23 | 0 | -3 | 2 | 1 |
| 31 Mar 23 | 0 | -3 | 2 | 1 |
| 31 Dec 22 | 0 | -3 | 2 | 1 |
| 30 Sep 22 | 0 | -3 | 2 | 1 |
| 30 Jun 22 | 0 | -3 | 2 | 1 |
| 31 Mar 22 | 0 | -3 | 2 | 1 |
| 31 Dec 21 | 0 | -3 | 3 | 0 |
| 30 Sep 21 | 0 | -3 | 2 | 0 |
| 30 Jun 21 | 0 | -2 | 2 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 0 | 1 |
Quality Earnings: ILA is currently unprofitable.
Growing Profit Margin: ILA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ILA is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare ILA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ILA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: ILA has a negative Return on Equity (-372.36%), as it is currently unprofitable.